Macrophage migration inhibitory factor mediates hypoxia- induced pulmonary hypertension

Molecular Medicine

Volumn 18, Issue 2, 2012, Pages 1-33

  Zhang, Yinzhong ^a   Talwar, Arunabh ^a,b,c   Tsang, Donna ^b   Bruchfeld, Annette ^d   Sadoughi, Ali ^a,b   Hu, Maowen ^a   Omonuwa, Kennedy ^b   Cheng, Kai Fan ^a   Al Abed, Yousef ^a,c   Miller, Edmund J ^a,b,c  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b North Shore LIJ Health System ^*  (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hypoxia; Macrophage migration inhibitory factor; Pulmonary hypertension; Vascular remodeling

Indexed keywords

CYTOKINE; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; OXYGEN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CHRONIC LUNG DISEASE; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; FIBROBLAST; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTERSTITIAL LUNG DISEASE; KNOCKOUT MOUSE; LONG TERM EXPOSURE; LUNG BLOOD VESSEL; MALE; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; WILD TYPE;

EID: 84859063201     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. McLaughlin VV AS, Badesch DB, et al. (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53: 1573-1619.
2. Stenmark KR, Fagan KA, Frid MG. (2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99: 675-691.
3. Tuder RM, Yun JH, Bhunia A, Fijalkowska I. (2007) Hypoxia and chronic lung disease. J Mol Med 85: 1317-1324.
4. Dorfmuller P, Perros F, Balabanian K, Humbert M. (2003) Inflammation in pulmonary arterial hypertension. Eur Respir J 22: 358-363.
5. Sadoughi A, Zhang Y, Miller EJ, Talwar A. (2010) Inflammatory mechanisms in pulmonary hypertension. (Leading Article). CML Pulmonary Hypertension 1: 93-106.
6. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. (2002) Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 4: 449-460.
7. Sakuragi T, Lin X, Metz CN, et al. (2007) Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression PMID: 17381395. Surg Infect (Larchmt) 8: 29-40.
8. Baugh JA, Gantier M, Li L, Byrne A, Buckley A, Donnelly SC. (2006) Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun 347: 895-903.
9. Welford SM, Bedogni B, Gradin K, Poellinger L, Broome Powell M, Giaccia AJ. (2006) HIF1alpha delays premature senescence through the activation of MIF. Genes Dev 20: 3366-3371.
10. Oda S, Oda T, Nishi K, et al. (2008) Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS One 3: e2215.
11. Winner M, Koong AC, Rendon BE, Zundel W, Mitchell RA. (2007) Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res 67: 186-193.
12. Mitchell RA, Metz CN, Peng T, Bucala R. (1999) Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274: 18100-18106.
13. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. (2003) Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 93: 321-329.
14. Pan JH, Sukhova GK, Yang JT, et al. (2004) Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109: 3149-3153.
15. Chen Z, Sakuma M, Zago AC, et al. (2004) Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol 24: 709-714.
16. Bruchfeld A, Carrero JJ, Qureshi AR, et al. (2009) Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation PMC2600496. Mol Med 15: 70-75.
17. Bozza M, Satoskar AR, Lin G, et al. (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189: 341-346.
18. Kumar RK, O'Grady R, Li W, Smith LW, Rhodes GC. (1991) Primary culture of adult mouse lung fibroblasts in serum-free medium: responses to growth factors. Exp Cell Res 193: 398-404.
19. Cheng KF, Al-Abed Y. (2006) Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem Lett 16: 3376-3379.
20. Li FH, Xia W, Li AW, Zhao CF, Sun RP. (2007) Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats. Chin Med J (Engl) 120: 22-29.
21. Le Pavec J, Launay D, Mathai SC, Hassoun PM, Humbert M. (2011) Scleroderma Lung Disease. Clin Rev Allerg Immu 40: 104-116.
22. Akgul F, Yalcin F, Seyfeli E, et al. (2007) Pulmonary hypertension in sickle-cell disease: Comorbidities and echocardiographic findings. Acta Haematol-Basel 118: 53-60.
23. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. (2007) Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 82: 342-350.
24. Domenighetti G. (2007) Prognosis, screening, early detection and differentiation of arterial pulmonary hypertension. Swiss Med Wkly 137: 331-336.
25. Dalonzo GE, Barst RJ, Ayres SM, et al. (1991) Survival in Patients with Primary Pulmonary-Hypertension-Results from a National Prospective Registry. Ann Intern Med 115: 343-349.
26. Jing ZC, Xu XQ, Han ZY, et al. (2007) Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 132: 373-379.
27. Puri A, McGoon MD, Kushwaha SS. (2007) Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin Pract Cardiovasc Med 4: 319-329.
28. Calandra T, Bernhagen J, Metz CN, et al. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377: 68-71.
29. Bacher M, Meinhardt A, Lan HY, et al. (1997) Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 150: 235-246.
30. Metz CN, Bucala R. (1997) Role of macrophage migration inhibitory factor in the regulation of the immune response. Adv Immunol 66: 197-223.
31. Calandra T, Echtenacher B, Roy DL, et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6: 164-170.
32. Al-Abed Y, Dabideen D, Aljabari B, et al. (2005) ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem. 280: 36541-36544.
33. Oyama R, Yamamoto H, Titani K. (2000) Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. Biochim Biophys Acta 1479: 91-102.
34. Eickhoff R, Baldauf C, Koyro HW, et al. (2004) Influence of macrophage migration inhibitory factor (MIF) on the zinc content and redox state of protein-bound sulphydryl groups in rat sperm: indications for a new role of MIF in sperm maturation. Mol Hum Reprod 10: 605-611.
35. Balabanian K, Foussat A, Dorfmuller P, et al. (2002) CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 1419-1425.
36. Dorfmuller P, Humbert M, Perros F, et al. (2007) Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 38: 893-902.
37. Pak O, Aldashev A, Welsh D, Peacock A. (2007) The effects of hypoxia on the cells of the pulmonary vasculature. Eur Respir J 30: 364-372.
38. Preston IR, Hill NS, Warburton RR, Fanburg BL. (2006) Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol 290: L367-374.
39. Frank DB, Abtahi A, Yamaguchi DJ, et al. (2005) Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res 97: 496-504.
40. Dempsey EC, McMurtry IF, O'Brien RF. (1991) Protein kinase C activation allows pulmonary artery smooth muscle cells to proliferate to hypoxia. Am J Physiol 260: L136-145.
41. Lanner MC, Raper M, Pratt WM, Rhoades RA. (2005) Heterotrimeric G proteins and the platelet-derived growth factor receptor-beta contribute to hypoxic proliferation of smooth muscle cells. Am J Respir Cell Mol Biol 33: 412-419.
42. Stiebellehner L, Frid MG, Reeves JT, Low RB, Gnanasekharan M, Stenmark KR. (2003) Bovine distal pulmonary arterial media is composed of a uniform population of well-differentiated smooth muscle cells with low proliferative capabilities. Am J Physiol Lung Cell Mol Physiol 285: L819-828.
43. Benitz WE, Coulson JD, Lessler DS, Bernfield M. (1986) Hypoxia inhibits proliferation of fetal pulmonary arterial smooth muscle cells in vitro. Pediatr Res 20: 966-972.
44. Rose F, Grimminger F, Appel J, et al. (2002) Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells: role of hypoxia-inducible transcription factors. Faseb J 16: 1660-1661.
45. Das M, Burns N, Wilson SJ, Zawada WM, Stenmark KR. (2008) Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKCzeta in the pulmonary artery adventitia. Cardiovasc Res 78: 440-448.
46. Stenmark KR, Davie N, Frid M, Gerasimovskaya E, Das M. (2006) Role of the adventitia in pulmonary vascular remodeling. Physiology (Bethesda) 21: 134-145.
47. Sartore S, Chiavegato A, Faggin E, et al. (2001) Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res 89: 1111-1121.
48. Belknap JK, Orton EC, Ensley B, Tucker A, Stenmark KR. (1997) Hypoxia increases bromodeoxyuridine labeling indices in bovine neonatal pulmonary arteries. Am J Respir Cell Mol Biol 16: 366-371.
49. Eul B, Rose F, Krick S, et al. (2006) Impact of HIF-1alpha and HIF-2alpha on proliferation and migration of human pulmonary artery fibroblasts in hypoxia. Faseb J 20: 163-165.
50. Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M. (2002) Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Chest 122: 326S-334S.
51. Dewor M, Steffens G, Krohn R, Weber C, Baron J, Bernhagen J. (2007) Macrophage migration inhibitory factor (MIF) promotes fibroblast migration in scratch-wounded monolayers in vitro. FEBS Lett 581: 4734-4742.
52. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190: 1375-1382.
53. Lue H, Kapurniotu A, Fingerle-Rowson G, et al. (2006) Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18: 688-703.
54. Swant JD, Rendon BE, Symons M, Mitchell RA. (2005) Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. J Biol Chem 280: 23066-23072.
55. Al-Abed Y, Dabideen D, Aljabari B, et al. (2005) ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 280: 36541-36544.
56. Crichlow GV, Cheng KF, Dabideen D, et al. (2007) Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor. J Biol Chem 282: 23089-23095.
57. Kleemann R, Kapurniotu A, Frank RW, et al. (1998) Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 280: 85-102.
58. Miller EJ, Li J, Leng L, et al. (2008) Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451: 578-582.
59. Koga K, Kenessey A, Powell S, Sison CP, Miller EJ, Ojamaa K. (2011) Macrophage Migration Inhibitory Factor Provides Cardioprotection during Ischemia/Reperfusion by Reducing Oxidative Stress. Antioxid Redox Signal 14: 1191-1202.